Oruka Therapeutics Inc

ORKA is in a Stage 3 distribution phase marked by a bearish pivot failure and EMAs crossed below the 50-SMA, signaling downward mean reversion. The medium-term bias is bearish, and any rally into the 9/20/50‐SMA resistance zone near $93–$95 should be faded. Short-term conditions are neutral rather than opportunistically bearish, so execution is deferred until a sign of rejection at dynamic resistance. The long-term uptrend above the rising 200-SMA remains intact but is currently overshadowed by structural distribution.

• ↑Phase 2a trial showed 63.5% of psoriasis patients reached complete clearance
• ↑Shares jumped 21.95% over two weeks, hitting a $109.56 52-week peak
• ↓Balance sheet shows high leverage risk that could restrict flexibility